591 related articles for article (PubMed ID: 26665262)
1. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
Lee CY; Suzuki JB
Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
Katz J; Ordoveza PA
Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
[TBL] [Abstract][Full Text] [Related]
4. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
5. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
[No Abstract] [Full Text] [Related]
7. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
Lee JJ; Cheng SJ; Wang YP; Jeng JH; Chiang CP; Kok SH
Head Neck; 2013 Jan; 35(1):E6-10. PubMed ID: 21523843
[TBL] [Abstract][Full Text] [Related]
9. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.
Magremanne M; Reychler H
J Oral Maxillofac Surg; 2014 Feb; 72(2):334-7. PubMed ID: 23891014
[TBL] [Abstract][Full Text] [Related]
10. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
11. Further development of the MRONJ minipig large animal model.
Otto S; Pautke C; Martin Jurado O; Nehrbass D; Stoddart MJ; Ehrenfeld M; Zeiter S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1503-1514. PubMed ID: 28803745
[TBL] [Abstract][Full Text] [Related]
12. Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis.
Kulkarni P; Cushman T; Donthireddy V; Rao S
BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26843222
[TBL] [Abstract][Full Text] [Related]
13. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
14. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
15. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
16. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
18. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
Lambrinoudaki I; Vlachou S; Galapi F; Papadimitriou D; Papadias K
Clin Interv Aging; 2008; 3(3):445-51. PubMed ID: 18982915
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment.
Gómez-Moreno G; Arribas-Fernández MC; Fernández-Guerrero M; Boquete-Castro A; Aguilar-Salvatierra A; Guardia J; Botticelli D; Calvo-Guirado JL
Eur Rev Med Pharmacol Sci; 2014; 18(9):1391-7. PubMed ID: 24867519
[TBL] [Abstract][Full Text] [Related]
20. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
Ringe JD; Nitschmann S
Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
